soul trial oral semaglutide cardiovascular outcomes 2025 results The (Semaglutide Trial) was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial that enrolled 9,650 patients aged 50 years or older with SOUL: Oral Semaglutide Bests Usual
Description
"Most GLP-1 supplements weren't designed for GLP-1 users
For every 100 people who start retatrutide, somewhere between 12 and 18 will find the side effects intolerable enough to stop
Because semaglutide slows down how fast your stomach empties, any discomfort you have from the virus may linger longer
Use a fresh, sterile needle every time
